Of the population, 1051 patients initiated a PPI and 5138 an H2 blocker from 2011 to 2018. Propensity-score and as-treated analyses showed similar trends. Proton pump inhibitors treat excess ...

Objective Proton pump inhibitors (PPIs) are widely used ... Participants Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included ...

Both pharmacokinetic and pharmacodynamic differences can be observed among the different proton pump inhibitors (PPIs), which might influence their clinical application. Pharmacokinetic Properties ...

Proton-pump inhibitors (PPIs) are the most effective medical therapy for patients with moderate-to-severe GERD and are widely prescribed to pregnant women. However, safety data about the use of ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

On a population level, the effects of PPI are more prominent than the effects of antibiotics or other commonly used drugs. Proton pump inhibitors (PPI) use is associated with increased risk of enteric ...

Keywords: Leaflet; Deprescription; Rational Use of Medicines; Proton Pump Inhibitors; Brazilian Health Regulatory Agency (ANVISA); Food and Drug Administration (FDA) In order to avoid or reduce the ...

People using proton pump inhibitors (PPIs), such as omeprazole and esomeprazole ... making them a potential concern for individuals with preexisting migraines or frequent headaches. While H2 blockers ...

Unconventional Computing Laboratory, University of the West of England, Bristol BS16 1QY, U.K.

Objectives The widespread use of proton pump inhibitors (PPIs) raised concerns on the safety of long-term use of these drugs. Community pharmacists have great responsibility of educating patients on ...

Other signs of an unhealthy gut may include vomiting or stomach upset, fatigue, trouble sleeping, food intolerance and other ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...